The DAWN and SEED trials demonstrate the potential of glucokinase activators for the treatment of type 2 diabetes, but how they fit in the overall treatment algorithm remains to be determined.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity
Nature Communications Open Access 14 March 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Matschinsky, F. M. Trends Pharmacol. Sci. 34, 90–99 (2013).
Grimsby, J. et al. Science 301, 370–373 (2003).
Guertin, K. R. & Grimsby, J. Curr. Med. Chem. 13, 1839–1843 (2006).
The Dawn Study Group. Nat. Med. https://doi.org/10.1038/s41591-022-01803-5 (2022).
The SEED Study Group. Nat. Med. https://doi.org/10.1038/s41591-022-01802-6 (2022).
De Ceuninck, F. et al. Br. J. Pharmacol. 168, 339–353 (2013).
Zhu, D. et al. Lancet Diabetes Endocrinol 6, 627–636 (2018).
Vella, A. et al. Sci. Transl. Med. 11, eaau3441 (2019).
Klein, K. R. et al. Diabetes Care 44, 960–968 (2021).
Chen, L. et al. Diabetes 70, 117–LB (2021).
Miao, J. et al. Clin. Transl. Sci. 15, 548–557 (2022).
American Diabetes Association Professional Practice Committee. Diabetes Care 45, S125–S143 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K.R.K. and J.B.B. have worked with vTv Therapeutics, the developers of the GKA TTP-399, as investigators and collaborators without direct financial benefit. J.B.B. has provided consultation to Novo Nordisk, with fees paid to the University of North Carolina; has grant support from Dexcom, NovaTarg, Novo Nordisk, Sanofi, Tolerion and vTv Therapeutics; is a consultant with personal compensation from Alkahest, Altimmune, Anji, AstraZeneca, Bayer, Boehringer-Ingelheim, CeQur, Cirius Therapeutics Inc., Dasman Diabetes Center (Kuwait), Eli Lilly, Fortress Biotech, GentiBio, Glycadia, Glyscend, Janssen, Mediflix, Medscape, Mellitus Health, Pendulum Therapeutics, Praetego, Stability Health, Valo and Zealand Pharma; and has received stock options from Glyscend, Mellitus Health, Pendulum Therapeutics, PhaseBio, Praetego and Stability Health.
Rights and permissions
About this article
Cite this article
Klein, K.R., Buse, J.B. A new class of drug in the diabetes toolbox. Nat Med 28, 901–902 (2022). https://doi.org/10.1038/s41591-022-01783-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-01783-6